Dermata Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Schedule of Equity Securities (Details) - shares	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares	260,000,000
Issued, shares	1,897,274
Abeyance, shares	388,700
Reserved, shares	13
Outstanding, shares	1,897,183
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares	250,000,000
Issued, shares	637,757
Abeyance, shares	388,700
Reserved, shares
Outstanding, shares	637,757	603,210	251,725	69,268	44,350	26,150
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares	10,000,000
Issued, shares
Abeyance, shares
Reserved, shares
Outstanding, shares
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares
Issued, shares	1,238,949
Abeyance, shares
Reserved, shares
Outstanding, shares	1,238,949
2021 Omnibus Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares
Issued, shares	20,568
Abeyance, shares
Reserved, shares	13
Outstanding, shares	20,477